<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine, 8e</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../j09u21sl.html">Pocket Medicine (Pocket Notebook Series)
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0014.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0016.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="ct"><a id="h114" class="calibre8"></a><a id="page_9-1" class="calibre8"></a><a href="part0003.html#rh126" class="calibre8">CHANGE IN MENTAL STATUS</a></h2>
<p class="h">Consciousness/Arousal <span class="r">(description of patient &amp; timing is most helpful)</span></p>
<p class="noindent1">• <b class="calibre7">Arousal:</b> spectrum from awake/alert → drowsy → stupor → coma. Terms vague &amp; subjective, so most useful to describe response to increasing stimulation (eg, voice → noxious).</p>
<p class="noindent1">• <b class="calibre7">Coma:</b> lack of response to external stimuli. Degree formalized in Glasgow Coma Scale. Caused by focal lesions in brainstem (reticular activating system), thalamus, or diffuse dysfxn of both cerebral hemispheres. Mimics: locked-in synd., akinetic mutism, catatonia.</p>
<p class="noindent1">• <b class="calibre7">Delirium/acute confusional state:</b> altered attention &amp; awareness, develops over hrs to days, often fluctuating, accompanied by cognitive Δs (eg, disorientation, memory loss, perceptual Δs); sometimes w/ sleep–wake dysregulation, autonomic Δs, emotionality</p>
<p class="noindent1">• <b class="calibre7">Dementia:</b> progressive cognitive impairment developing over mos to yrs; often affects memory, language, visuospatial, and executive function; attention often spared</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Etiologies of Decreased Responsiveness</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody">1<b class="calibre7">° Neurologic</b> (<i class="calibre6">usually with focal signs</i>)</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Systemic</b> (<i class="calibre6">esp. in elderly or prior CNS injury</i>)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh">Vasc: ischemic stroke/TIA, ICH, VST, PRES, vasculitis, pituitary apoplexy</p>
<p class="tbodyh">Seizure: postictal, status, nonconvulsive</p>
<p class="tbodyh">Infxn: meningitis, encephalitis, abscess</p>
<p class="tbodyh">Trauma: TBI, concussion, diffuse axonal injury</p>
<p class="tbodyh">↑ intracranial pressure: mass, edema, hydrocephalus, herniation</p>
<p class="tbodyh">Autoimmune/paraneoplastic enceph.</p>
<p class="tbodyh">Neurodeg: late-stage (eg, Alzheimer’s) or rapidly progressive (eg, CJD)</p></td>
<td class="th1"><p class="tbodyh">Cardiac: global ischemia, HoTN, HTN enceph</p>
<p class="tbodyh">Pulmonary: ↓ P<sub class="calibre17">a</sub>O<sub class="calibre17">2</sub>, ↑ P<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub></p>
<p class="tbodyh">GI: liver failure, ↑ NH<sub class="calibre17">3</sub></p>
<p class="tbodyh">Renal: uremia, dialysis, ↓ or ↑ Na, ↓ or ↑ Ca</p>
<p class="tbodyh">Heme: TTP/HUS, DIC, hyperviscosity</p>
<p class="tbodyh">Endo: ↓ glc, DKA/HHNS, hypothyr., Addisonian</p>
<p class="tbodyh">ID: pneumonia, UTI, endocarditis, sepsis</p>
<p class="tbodyh">Hypothermia &amp; hyperthermia</p>
<p class="tbodyh">Meds: anticholin., anti-hist., psychotrop., digoxin</p>
<p class="tbodyh">Toxins/withdrawal: EtOH, sedative, opiate, CO</p>
<p class="tbodyh">Psychiatric: catatonia, serotonin synd., NMS</p></td>
</tr>
</tbody>
</table>
<p class="h">Initial evaluation</p>
<p class="noindent1">• <b class="calibre7">History</b> (witness &amp; background <i class="calibre6">crucial</i>): tempo, premorbid sx (eg, focal neuro deficits, HA, infxn, pain, falls), medical conditions (eg, dementia, epilepsy, onc, cardiac, psych, infection/immune status), accompanied by head trauma, current meds (eg, sedatives, opioids, anticoag, anticonvulsants, immunosuppressants), drug/alcohol use</p>
<p class="noindent1">• <b class="calibre7">General exam:</b> <i class="calibre6">VS</i>, breathing pattern (eg, Cheyne-Stokes), tongue bite (seizure), <i class="calibre6">nuchal rigidity</i> (meningitis, SAH; <i class="calibre6">do not test</i> if c/f trauma/cervical spine fx), ecchymoses, rash, signs of head trauma (eg, Battle sign, raccoon eyes, hemotympanum, CSF rhinorrhea), asterixis, liver disease stigmata, embolic phenomena/endocarditis, s/s drug use</p>
<p class="noindent1">• <b class="calibre7">Neuro exam</b> (see below): perform off sedatives/paralytics if possible, look for focal deficits suggesting structural cause (eg, stroke, herniation), s/s of ↑ ICP (eg, HA, vomiting, papilledema, abducens nerve palsy, unilateral dilated pupil, ↑ BP/↓ HR, fixed downgaze)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td colspan="2" class="th"><p class="tbodyc"><b class="calibre7">Neuro Exam in Patients with Decreased Responsiveness</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody">Mental status</p></td>
<td class="th1"><p class="tbodyh">Arousal (behavioral response to ↑ intensity of stimulation, GCS)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Cranial nerves</p></td>
<td class="th1"><p class="tbodyh">Pupils: <i class="calibre6">pinpoint</i> → opiates, pontine lesion; <i class="calibre6">midposition &amp; fixed</i> → midbrain lesion; <i class="calibre6">fixed &amp; dilated</i> → severe anoxic injury, herniation, anti-cholin.</p>
<p class="tbodyh">Extraocular movements / vestibulo-ocular reflex tests:</p>
<p class="tbodyh">Oculocephalic maneuver (“doll’s eyes”): nl = eyes move opposite head movement (do not test if possible cervical spine trauma)</p>
<p class="tbodyh">Vestibular (cold) caloric stimulation: in coma, nl = eyes move slowly to lavaged ear, then quickly away (<i class="calibre6">do not test w tymp memb perf)</i></p>
<p class="tbodyh">Corneal reflex, facial grimace to nasal tickle</p>
<p class="tbodyh">Gag &amp; cough reflexes (with ET tube manipulation if necessary)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Motor</p></td>
<td class="th1"><p class="tbodyh">Tone, spont movements, flexor/extensor posturing of arms/legs, strength</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Sensory</p></td>
<td class="th1"><p class="tbodyh">Response to painful stimuli: purposeful vs. reflexive/posturing</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Reflexes</p></td>
<td class="th1"><p class="tbodyh">Deep tendon reflexes, Babinski, “triple” flexion (ankle, knee, &amp; hip flexion to noxious stimulation → not suggestive of intact cortical function)</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre20"/>
<col class="calibre33"/>
<col class="calibre25"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td colspan="4" class="th"><p class="tbodyc"><b class="calibre7">Glasgow Coma Scale</b> (sum points from each of 3 categories to calculate score)</p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Eye Opening</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Best Verbal Response</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Best Motor Response</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Points</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbodyh"> </p></td>
<td class="th1"><p class="tbodyc">Follows commands</p></td>
<td class="th1"><p class="tbodyc">6</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbodyc">Oriented</p></td>
<td class="th1"><p class="tbodyc">Localizes pain</p></td>
<td class="th1"><p class="tbodyc">5</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Spontaneous</p></td>
<td class="th1"><p class="tbodyc">Confused</p></td>
<td class="th1"><p class="tbodyc">Withdraws from pain</p></td>
<td class="th1"><p class="tbodyc">4</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">To voice</p></td>
<td class="th1"><p class="tbodyc">Inappropriate words</p></td>
<td class="th1"><p class="tbodyc">Flexor posturing</p></td>
<td class="th1"><p class="tbodyc">3</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">To painful stimuli</p></td>
<td class="th1"><p class="tbodyc">Unintelligible sounds</p></td>
<td class="th1"><p class="tbodyc">Extensor posturing</p></td>
<td class="th1"><p class="tbodyc">2</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">None</p></td>
<td class="th1"><p class="tbodyc">None (intubated = 1T)</p></td>
<td class="th1"><p class="tbodyc">None</p></td>
<td class="th1"><p class="tbodyc">1</p></td>
</tr>
</tbody>
</table>
<p class="h"><a id="page_9-2" class="calibre4"></a>Initial treatment</p>
<p class="noindent1">• Empiric antibiotics if c/f CNS infection: vancomycin/CTX, consider acyclovir and ampicillin</p>
<p class="noindent1">• Immobilization of C-spine if concern for cervical trauma</p>
<p class="noindent1">• Thiamine 100 mg IV → dextrose 50 g IVP (this order to prevent exacerbation of Wernicke’s)</p>
<p class="noindent1">• If opiates suspected: naloxone 0.01 mg/kg; if BDZ suspected, consider flumazenil 0.2 mg IV</p>
<p class="noindent1">• If concern for ↑ ICP ↑ herniation: ↑ head of bed; osmotherapy w/ mannitol or hypertonic saline; ↑ ventilation; dexamethasone for tumor edema; c/s neurosurgery (? decompress)</p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2014;384:2064)</span></p>
<p class="noindent1">• All patients: check fingerstick glucose, electrolytes, BUN/Cr, LFTs, CBC, tox screen, U/A</p>
<p class="noindent1">• <i class="calibre6">Based on clinical suspicion:</i></p>
<p class="noindent2">Labs: NH<sub class="calibre10">3</sub>, TSH, cort stim, B<sub class="calibre10">12</sub>, ABG, HIV, ESR, ANA, TPO/anti-TG, BCx, drug levels</p>
<p class="noindent2">Imaging: head CT, then MRI; CTA if c/f stroke/SAH; radiographs to r/o C-spine fracture</p>
<p class="noindent2">Lumbar puncture to r/o meningitis, SAH, or noninfectious inflammation (eg, autoimmune)</p>
<p class="noindent2">EEG to evaluate for nonconvulsive seizures, toxic/metabolic encephalopathy</p>
<p class="h">Further treatment of delirium <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2017;377:1456)</span></p>
<p class="noindent1">• Treat underlying acute illness, eliminate precipitating factors, &amp; provide supportive care</p>
<p class="noindent1">• Address sensory &amp; cognitive impairments (frequent reorientation, glasses/hearing aids, etc.)</p>
<p class="noindent1">• Decrease/prevent infection/restraints if possible, remove lines/catheters if unnecessary</p>
<p class="noindent1">• Promote good sleep: reduce noise &amp; nighttime interventions; sedative med if necessary</p>
<p class="noindent1">• Meds: consider antipsychotics (but neither haloperidol nor ziprasidone ↓ delirium duration in ICU Pts; <span class="r2">NEJM</span> <span class="r1">2018;379:2506</span>); avoid benzos except in EtOH withdrawal or seizures</p>
<p class="h1cr">A<small class="calibre31">NOXIC</small> B<small class="calibre31">RAIN</small> I<small class="calibre31">NJURY</small> <span class="r5">(at risk if ≥5 min cerebral hypoxia)</span></p>
<p class="h">Initial evaluation <span class="r1">(</span><span class="r2">Circulation</span><span class="r1"> 2010:S768)</span></p>
<p class="noindent1">• Neuro exam: arousal/verbal, eyes &amp; other cranial nerves, motor response to pain</p>
<p class="noindent1">• Imaging: CT usually not informative w/in first day after arrest, but should be done prior to initiating targeted temp management if patient found down or has had head trauma</p>
<p class="h">Targeted temperature management <span class="r1">(</span><span class="r2">Circulation</span> <span class="r1">2015;132:2448)</span></p>
<p class="noindent1">• Indications: comatose (GCS &lt;8) w/in 6 h after cardiac arrest (not isolated resp. arrest). Beneficial in both VT/VF and PEA/asystole. Also consider 6–12 h post-arrest.</p>
<p class="noindent1">• Relative contraindic.: major head trauma, coagulopathy/bleeding, major surgery &lt;14 d; CV instability no longer viewed as contraindication, but rather something to be managed.</p>
<p class="noindent1">• Target temp: 32–37.8°C × ≥24 h, rewarm, then maintain normothermia (37°C) for ~24 hrs.</p>
<p class="noindent1">• Initial studies showing benefit w/ 32–34°C, but subsequent studies showed ≈ outcomes for 36°C or 37.8°C vs. 33°C <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;369:2197 &amp; 2021;384:2283)</span></p>
<p class="noindent1">• ∴ <i class="calibre6">prevent hyperthermia</i>, but need for hypothermia vs. normothermia unclear</p>
<p class="noindent1">• Method: ice packs to head/neck/torso; cooling blankets; cooling vest or endovascular catheter. Goal to achieve target temp &lt;6 h. Pts should be sedated/paralyzed while cooled. Start rewarming 24 h after cooling initiated (rewarm ≤0.5°C per h).</p>
<p class="noindent1">• Can consider higher MAP goal of &gt;70 mmHg</p>
<p class="noindent1">• Complications</p>
<p class="noindent2">Dysrhythmias (brady most common): if significant or hemodynamic instability → rewarm</p>
<p class="noindent2">Coagulopathy (can receive lytics, GP IIb/IIIa inhibitors, etc.); monitor PT &amp; PTT</p>
<p class="noindent2">Infection: monitor surveillance blood cultures during cooling</p>
<p class="noindent2">Hyperglycemia during cooling, hypoglycemia w/ rewarming; stop insulin if glc &lt;200 mg/dL</p>
<p class="noindent2">Hypokalemia during cooling, hyperkalemia w/ rewarming; keep K 4–5 mEq/L</p>
<p class="h">Ongoing evaluation</p>
<p class="noindent1">• Neuro exam: daily focus on coma exam. No exam finding is reliable &lt;24 h or on sedation. Should be off sedation for adequate time (depends on dose, duration, Pt’s metabolism).</p>
<p class="noindent1">• Labs: daily CBC, PT/PTT, electrolytes. Serum neuron-specific enolase (NSE) on days 1–3.</p>
<p class="noindent1">• Imaging: noncontrast CT 24 h after arrest; if unrevealing, consider MRI around days 3–5</p>
<p class="noindent1">• EEG: consider in all to exclude seizures; greatest risk during rewarming. Unreactive background or abundant rhythmic or episodic discharges may convey poor prognosis.</p>
<p class="noindent1">• Somatosensory evoked potentials (SSEP): helpful for prediction of poor outcome if cortical responses are absent bilaterally; perform 48 h after arrest (72 h if cooled)</p>
<p class="h">Prognosis <span class="r1">(</span><span class="r2">Nat Rev Neuro</span> <span class="r1">2014;10:190)</span></p>
<p class="noindent1">• Prior to cooling era, poor prognosis at 72 h if absent pupillary &amp; corneal reflexes and no motor response to pain; or absent SSEPs at 48 h. With cooling, unclear if prior measures as reliable. Overall ~12% survive to hosp. d/c; VT/VF 25-40%, PEA ~10%, asystole ~2%.</p>
<p class="noindent1">• Prognosis requires multifactorial assessment based on age, exam, comorbidities, ancillary data. Poor signs: absent brainstem reflexes, Rx-resistant myoclonus, EEG w/ absent background/reactivity, NSE &gt;101, MRI w/ diffuse hypoxic injury. If doubt, err on more time.</p>
<h2 class="ct"><a id="h115" class="calibre8"></a><a id="page_9-3" class="calibre8"></a><a href="part0003.html#rh127" class="calibre8">SEIZURES</a></h2>
<p class="h">Definitions &amp; clinical manifestations <span class="r1">(</span><span class="r2">Epilepsia</span><span class="r1"> 2017;58:522)</span></p>
<p class="noindent1">• <b class="calibre7">Seizure:</b> transient neurologic symptoms due to excessive synchronous neuronal activity; may be <i class="calibre6">provoked</i> by a reversible factor lowering the seizure threshold, or <i class="calibre6">unprovoked</i></p>
<p class="noindent1">• <b class="calibre7">Epilepsy:</b> ≥2 unprovoked seizures occurring &gt;24 h apart <i class="calibre6">or</i> 1 unprovoked seizure w/ ≥60% probability of further seizures over the next 10 y (see below for prognostication)</p>
<p class="noindent1">• <b class="calibre7">Generalized seizures</b> (involves brain diffusely)</p>
<p class="noindent2"><i class="calibre6">Tonic-clonic</i> (grand mal):</p>
<p class="noindent3"><b class="calibre7">Aura</b> (sec to mins): premonition with paresthesias, focal motor contractions, abnormal smells/tastes, fear, depersonalization, déjà vu, autonomic changes, automatisms</p>
<p class="noindent3"><b class="calibre7">Ictal period</b> (sec to mins): lateral gaze and head deviation, tonic contraction of muscles → intermittent relaxing and tensing of muscles, tongue biting, urinary incontinence, pooling of secretions</p>
<p class="noindent3"><b class="calibre7">Postictal period</b> (mins to h): slowly resolving period of confusion, disorientation, and lethargy. May be accompanied by focal neurologic deficits (Todd’s paralysis).</p>
<p class="noindent2"><i class="calibre6">Absence</i> (petit mal): transient lapse of consciousness w/o loss of postural tone, usu pedi</p>
<p class="noindent2"><i class="calibre6">Myoclonic</i> (infantile spasms &amp; juvenile myoclonic epilepsy): sudden, brief contraction</p>
<p class="noindent1">• <b class="calibre7">Focal seizures</b> (involves discrete brain area, often associated with a structural lesion)</p>
<p class="noindent2"><i class="calibre6">w/o impaired awareness:</i> focal motor/autonomic sx (formerly “simple partial seizure”) or focal sensory/psychic symptoms (eg, aura)</p>
<p class="noindent2"><i class="calibre6">w/ impaired awareness:</i> dyscognitive features (formerly “complex partial seizure”)</p>
<p class="noindent2"><i class="calibre6">evolving to bilateral, convulsive seizure</i> (formerly “secondarily generalized seizure”)</p>
<p class="noindent1">• <b class="calibre7">Status epilepticus:</b> continuous convulsive seizure ≥5 min or &gt;2 seizures w/o resolution of postictal encephalopathy; <i class="calibre6">life threatening</i></p>
<p class="noindent1">• <b class="calibre7">Nonconvulsive status epilepticus:</b> alteration of awareness (ranging from confusion to coma) w/o motor manifestations of seizure; dx with EEG</p>
<p class="h">Differential diagnosis</p>
<p class="noindent1">• <b class="calibre7">Syncope</b> <span class="r1">(</span><span class="r2">Lancet Neurol</span> <span class="r1">2006;5:171)</span></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre30"/>
<col class="calibre30"/>
<col class="calibre37"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbodyc"><b class="calibre7">Feature</b></p></td>
<td class="th"><p class="tbodyc"><b class="calibre7">Seizure</b></p></td>
<td class="th"><p class="tbodyc"><b class="calibre7">Syncope</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Aura</p></td>
<td class="th1"><p class="tbodyc">Unusual behavior/automatisms</p></td>
<td class="th1"><p class="tbodyc">Diaphoresis, nausea, tunnel vision</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Convulsions</p></td>
<td class="th1"><p class="tbodyc">Variable duration</p></td>
<td class="th1"><p class="tbodyc">Usually &lt;10 sec</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Postictal state</p></td>
<td class="th1"><p class="tbodyc">Yes; can be ≥30 min</p></td>
<td class="th1"><p class="tbodyc">None or short</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Other clues</p></td>
<td class="th1"><p class="tbodyc">Tongue biting, incontinence</p></td>
<td class="th1"><p class="tbodyc">Skin pallor, clamminess</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• <b class="calibre7">Nonepileptic seizure</b> (aka “psychogenic”): may see side-to-side head turning, asymmetric large-amplitude limb movements, hip thrusting, diffuse shaking w/o LOC, crying/talking during event; diagnosis requires spell capture on EEG with no EEG correlate</p>
<p class="noindent1">• Other: metabolic disorders (eg, alcoholic blackouts, hypoglycemia), migraine, TIA, transient global amnesia, narcolepsy (cataplexy), nonepileptic myoclonus, tics, asterixis</p>
<p class="h">Etiologies of seizures <span class="r">(vary strongly by age)</span></p>
<p class="noindent1">• <b class="calibre7">Without focal lesion:</b> genetic predisposition to seizures or epilepsy syndrome; alcohol withdrawal, illicit drugs; meds (eg, β-lactams, bupropion, fluoroquinolones, tramadol, MNZ, meperidine, CsA); electrolyte (hyponatremia) &amp; other metabolic (eg, uremia, liver failure, hypoglycemia); autoimmune encephalitis, idiopathic (~60%)</p>
<p class="noindent1">• <b class="calibre7">With focal lesion:</b> tumor, trauma, stroke, subdural hematomas, posterior reversible encephalopathy syndrome, mesial temporal sclerosis, abscess, focal cortical dysplasia</p>
<p class="h">Clinical evaluation <span class="r1">(</span><span class="r2">JAMA</span><span class="r1"> 2016;316:2657)</span></p>
<p class="noindent1">• <i class="calibre6">History key in differentiating seizure from other causes of transient loss of consciousness</i>. Must talk to witnesses. Ask about prodrome, unusual behavior before spell, type &amp; pattern of abnl movements incl. head turning &amp; eye deviation (gaze preference usually <i class="calibre6">away</i> from seizure focus), loss of responsiveness.</p>
<p class="noindent1">• Recent events: illnesses/fevers, head trauma, sleep deprivation, stressors</p>
<p class="noindent1">• PMH: prior seizures or ⊕ FHx; prior CNS infection, stroke or head trauma; dementia</p>
<p class="noindent1">• Medications (new or noncompliance), alcohol and illicit drug use</p>
<p class="noindent1">• General physical exam should include the skin, looking for neuroectodermal disorders (eg, neurofibromatosis, tuberous sclerosis) that are a/w seizures</p>
<p class="noindent1">• Neurologic exam should look for focal abnormalities → underlying structural abnormality</p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">Neurology</span><span class="r1"> 2007;69:1996)</span></p>
<p class="noindent1">• Lab: full lytes, BUN, Cr, glc, LFTs, CK, lactate, tox screen, AED levels (except levetiracetam level rarely useful unless ? noncompliance), illicit drug screen, prolactin if drawn immediately after event (w/in 10–20 min)</p>
<p class="noindent1">• Routine EEG (~30 min): may help determine risk of seizure recurrence after 1<sup class="calibre19">st</sup>-time unprovoked seizure. Caveat: interictal EEG nl in 50% of Pts w/ epilepsy, and interictal <a id="page_9-4" class="calibre4"></a>epileptiform activity (spikes or sharp waves) seen in up to 2% of nl population; EEG w/in 24 h, sleep deprivation and repeated studies ↑ dx yield of EEG.</p>
<p class="noindent1">• Long-term EEG monitoring (hrs to days): if suspicion for nonconvulsive status or non-epileptic seizures; video monitoring may help w/ nonepileptic seizures</p>
<p class="noindent1">• MRI to r/o structural abnormalities; ↑ Se w/ fine coronal imaging of frontal &amp; temporal lobes</p>
<p class="noindent1">• LP (if no space-occupying lesion on imaging): if suspect meningoencephalitis (eg, fever, ↑ WBC, nuchal rigidity), autoimmune encephalitis, and in <i class="calibre6">all</i> HIV ⊕ Pts</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Neurology</span><span class="r1"> 2015;84:1705;</span> <span class="r2">Lancet</span><span class="r1"> 2015;385:884)</span></p>
<p class="noindent1">• Treat any underlying precipitants, including CNS infections, intoxication, withdrawal, discontinuing provoking med, etc.</p>
<p class="noindent1">• Antiepileptic drug (AED) Rx usually reserved for Pts w/ ≥2 <i class="calibre6">unprovoked</i> seizures, single seizure w/ high risk of recurrence (see below), or underlying structural abnormality. <i class="calibre6">Provoked</i> seizures generally treated by addressing underlying cause; consider AED if status epilepticus on presentation, focal neuro exam, postictal Todd’s paralysis.</p>
<p class="noindent1">• After 1<sup class="calibre19">st</sup> unprovoked sz, weigh risks of recurrence vs. AED. ↑ risk of recurrence if abnl EEG, MRI, or nocturnal sz. If EEG &amp; MRI nl → 65% sz-free at 5 y <span class="r1">(</span><span class="r2">Lancet Neurol</span> <span class="r1">2006;5:317)</span>.</p>
<p class="noindent1">• Immediate treatment w/ AED after 1<sup class="calibre19">st</sup> unprovoked seizure ↓ risk of recurrence over 2 y, but does not Δ long-term prognosis</p>
<p class="noindent1">• If AED Rx indicated, choice dependent on type of seizure, side effects, cost, mechanism of elimination (if hepatic or renal insufficiency), teratogenesis, and drug interactions</p>
<p class="noindent1">• Introduce gradually, monitor carefully</p>
<p class="noindent1">• Individual state laws mandate seizure-free duration before being allowed to drive</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre12"/>
<col class="calibre20"/>
<col class="calibre20"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Antiepileptic Drugs and Side Effects</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="tb" rowspan="2"><p class="tbody"><b class="calibre7">Medication</b></p></td>
<td class="tb" rowspan="2"><p class="tbody"><b class="calibre7">Avg Daily Dose</b></p></td>
<td class="th1" colspan="2"><p class="tbodyc"><b class="calibre7">Common Side Effects</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">Systemic</i></p></td>
<td class="th1"><p class="tbody"><i class="calibre6">Neurologic</i></p>
<p class="tbody"><i class="calibre6">(all: sedation)</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Carbamazepine</p></td>
<td class="th1"><p class="tbody">400–1600 mg</p></td>
<td class="th1"><p class="tbody">Aplastic anemia, ↓ WBC, rash, hepatotoxicity, ↓ Na</p></td>
<td class="th1"><p class="tbody">Diplopia, confusion, ataxia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Ethosuximide</p></td>
<td class="th1"><p class="tbody">500–1500 mg</p></td>
<td class="th1"><p class="tbody">Rash, BM suppression</p></td>
<td class="th1"><p class="tbody">Behavioral Δs</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Gabapentin</p></td>
<td class="th1"><p class="tbody">900–3600 mg</p></td>
<td class="th1"><p class="tbody">GI upset, wt gain</p></td>
<td class="th1"><p class="tbody">Nystagmus, ataxia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Lacosamide</p></td>
<td class="th1"><p class="tbody">200–400 mg</p></td>
<td class="th1"><p class="tbody">Prolonged PR interval</p></td>
<td class="th1"><p class="tbody">Dizziness, diplopia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Lamotrigine</p></td>
<td class="th1"><p class="tbody">100–300 mg</p></td>
<td class="th1"><p class="tbody">Rash (Stevens-Johnson)</p></td>
<td class="th1"><p class="tbody">Tremor, HA, blurred vision, insomnia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Levetiracetam</p></td>
<td class="th1"><p class="tbody">1000–3000 mg</p></td>
<td class="th1"><p class="tbody">GI upset (rare)</p></td>
<td class="th1"><p class="tbody">Emotional lability</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Oxcarbazepine</p></td>
<td class="th1"><p class="tbody">600–2400 mg</p></td>
<td class="th1"><p class="tbody">Hyponatremia, rash</p></td>
<td class="th1"><p class="tbody">Diplopia, dizziness</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Phenobarbital</p></td>
<td class="th1"><p class="tbody">50–200 mg</p></td>
<td class="th1"><p class="tbody">Rash</p></td>
<td class="th1"><p class="tbody">Cognitive slowing</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Phenytoin</p></td>
<td class="th1"><p class="tbody">200–400 mg</p></td>
<td class="th1"><p class="tbody">Gum hyperplasia</p></td>
<td class="th1"><p class="tbody">Dizziness, ataxia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Topiramate</p></td>
<td class="th1"><p class="tbody">100–400 mg</p></td>
<td class="th1"><p class="tbody">↓ wt, hypohidrosis, kidney stones, glaucoma, met acid</p></td>
<td class="th1"><p class="tbody">Cognitive slowing</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Valproic acid</p></td>
<td class="th1"><p class="tbody">500–2500 mg</p></td>
<td class="th1"><p class="tbody">Hepatotox, ↑ NH<sub class="calibre17">3</sub>, ↑ wt, ↓ hair</p></td>
<td class="th1"><p class="tbody">Tremor</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Zonisamide</p></td>
<td class="th1"><p class="tbody">200–600 mg</p></td>
<td class="th1"><p class="tbody">↓ wt, hypohidrosis, nephrolith</p></td>
<td class="th1"><p class="tbody">Cog slowing, fatigue</p></td>
</tr>
</tbody>
</table>
<p class="tfn">(<i class="calibre6">NEJM</i> 2008;359:166; <i class="calibre6">Lancet Neurol</i> 2011;10:446)</p>
<p class="h">Status epilepticus <span class="r1">(</span><span class="r2">Epilepsy Curr</span> <span class="r1">2016;16:48)</span></p>
<p class="noindent1">• ABCs: vital signs, oral airway or endotracheal intubation. Place Pt in semiprone position to ↓ risk of aspiration. Obtain IV access. Give thiamine, dextrose, IV normal saline.</p>
<p class="noindent1">• STAT POC glc, metabolic panel, CBC, tox screen, CK, lactate, AED levels, consider head CT, LP</p>
<p class="noindent1">• Start standing AED after loading dose.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre25"/>
<col class="calibre23"/>
<col class="calibre23"/>
<col class="calibre33"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Treatment of Status Epilepticus</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Time (min)</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Antiepileptic</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Dosing Regimen</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Typical Adult Dose</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">5–20</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Lorazepam</b> or</p>
<p class="tbody"><b class="calibre7">Midazolam</b> or</p>
<p class="tbody"><b class="calibre7">Diazepam<sup class="calibre27"><a id="fn193-s1" class="calibre8"></a><a href="part0015.html#rfn193-s1" class="calibre8">*</a></sup></b></p></td>
<td class="th1"><p class="tbody">0.1 mg/kg IV&gt;IM</p>
<p class="tbody">0.2 mg/kg IM</p>
<p class="tbody">0.2 mg/kg IV or 0.2–0.5 mg/kg PR</p></td>
<td class="th1"><p class="tbody">2–4 mg IV pushes, up to 8 mg Up to 10 mg x1</p>
<p class="tbody">Up to 10 mg IV; up to 20 mg PR</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">20–40</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Phenytoin</b> or <b class="calibre7">Fosphenytoin</b> or <b class="calibre7">Valproate</b> or</p>
<p class="tbody"><b class="calibre7">Levetiracetam</b></p></td>
<td class="th1"><p class="tbody">20 mg/kg</p>
<p class="tbody">20 mg PE/kg</p>
<p class="tbody">40 mg/kg</p>
<p class="tbody">20–40 mg/kg</p></td>
<td class="th1"><p class="tbody">1.0–1.5 g IV (max 1.5 g) over 20 min</p>
<p class="tbody">1.0–1.5 g PE IV over 5–10 min</p>
<p class="tbody">1.0–1.5 g IV (max 3 g) over 5–10 min</p>
<p class="tbody">2g IV (max 4.5 g) over 10–15 min</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td class="th1" colspan="3"><p class="tbody"><i class="calibre6">Subsequent steps mandate intubation, EEG monitoring, and ICU admission</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">40–60</p></td>
<td class="th1" colspan="3"><p class="tbody">General anesthesia with continuous midazolam, pentobarbital, or propofol</p></td>
</tr>
</tbody>
</table>
<p class="tfn">PE, phenytoin equivalents. <sup class="calibre22"><a id="rfn193-s1" class="calibre8"></a><a href="part0015.html#fn193-s1" class="calibre8">*</a></sup>Consider PR diazepam if no IV access and IM midazolam is contraindicated.</p>
<h2 class="ct"><a id="h116" class="calibre8"></a><a id="page_9-5" class="calibre8"></a><a href="part0003.html#rh128" class="calibre8">ALCOHOL WITHDRAWAL</a></h2>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Minor withdrawal: 6–48 h after last drink; mild anxiety, tremulousness, HA</p>
<p class="noindent1">• <b class="calibre7">Withdrawal seizures:</b> typically w/in 48 h after last drink; if unRx’d, 1/3 → delirium tremens</p>
<p class="noindent1">• <b class="calibre7">Alcoholic hallucinosis:</b> isolated hallucinations (typically visual) 12–48 h after last drink</p>
<p class="noindent1">• <b class="calibre7">Delirium tremens</b> (<b class="calibre7">DT</b>): disorientation, agitation, hallucinations, ↑ HR &amp; BP, fever, diaphoresis; begins 48–96 h after last drink, lasts 5–7 d</p>
<p class="noindent1">• Consider other dx: CNS infxn or bleed, sz, drug O/D, co-ingestions, acute liver failure, GIB</p>
<p class="noindent1">• Ten-item scale (CIWA-Ar) used to assess and manage alcohol withdrawal (see Appendix)</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">J Addict Med</span> <span class="r1">2020;14:1)</span></p>
<p class="noindent1">• <b class="calibre7">Benzodiazepines</b>:</p>
<p class="noindent2">Drug: diazepam preferred (long-acting; ↓ risk of recurrent withdrawal), lorazepam (short-acting), chlordiazepoxide, oxazepam (no active metab; good if cirrhosis)</p>
<p class="noindent2">Dosing: typically start w/ diazepam 10–15 mg IV q10–15min (or lorazepam 2–4 mg IV q15–20min) until appropriate sedation achieved, then titrate to CIWA-Ar scale, evaluating q1–4 h until score &lt;10 × 24 h, then q4–8 h × 24 h, and if stable, then q4 h</p>
<p class="noindent1">• <b class="calibre7">Phenobarbital:</b> adjunctive use in severe withdrawal may ↓ hospital stay, mech ventilation</p>
<p class="noindent1">• <i class="calibre6">Avoid</i> βB (mask sx)</p>
<p class="noindent1">• Mechanical restraints as needed until chemical sedation achieved</p>
<p class="noindent1">• Volume resuscitation as needed; thiamine <i class="calibre6">then</i> glc to prevent <i class="calibre6">Wernicke’s encephalopathy</i> (ataxia, ophthalmoplegia, short-term memory loss); replete K, Mg, PO<sub class="calibre10">4</sub></p>
<p class="noindent1">• Ppx: if min sx or asx (ie, CIWA score &lt;8) but prolonged heavy EtOH consumption or h/o withdrawal seizures or DTs → chlordiazepoxide 25–100 mg q6 h × 24 h, then taper</p>
<h2 class="ct"><a id="h117" class="calibre8"></a><a href="part0003.html#rh129" class="calibre8">DIZZINESS</a></h2>
<p class="h">Differential diagnosis</p>
<p class="noindent1">• Includes a variety of sx. <b class="calibre7">Disequilibrium:</b> sense of imbalance, gait disturbance;<b class="calibre7"> vertigo:</b> perception of spinning;<b class="calibre7"> near syncope:</b> lightheadedness due to cerebral hypoperfusion.</p>
<p class="noindent1">• Dizziness can occur with PNS &amp; CNS injury (vide infra) or in hematologic (eg, anemia), CV (eg, arrhythmia, orthostasis) &amp; endocrine (eg, ↓ glc, thyroid) disorders, or due to meds</p>
<p class="noindent1">• Vertigo Ddx:</p>
<p class="noindent2"><i class="calibre6">Peripheral (inner ear/CNVIII)</i></p>
<p class="noindent3"><b class="calibre7">BPPV:</b> dislodged canaliths in semicircular canal; episodic rotatory vertigo (&lt;1 min episodes), triggered by changes in position; Rx: Epley/BBQ roll maneuver</p>
<p class="noindent3"><b class="calibre7">Meniere’s disease:</b> ↑ endolymphatic pressure in inner ear; episodic rotatory vertigo (min-hrs), N/V, aural fullness, hearing loss, tinnitus; Rx: diuretics, ↓ salt</p>
<p class="noindent3"><b class="calibre7">Vestibular neuritis:</b> sudden-onset w/ gait ataxia; severe for 24–48 hrs followed by gradual improvement, often post-viral; w/ hearing loss = labyrinthitis</p>
<p class="noindent2"><i class="calibre6">Central (brainstem/cerebellum)</i></p>
<p class="noindent3"><b class="calibre7">Posterior circulation stroke/TIA:</b> “5 Ds” of dizziness, diplopia, dysarthria, dysphagia, dystaxia; sudden onset (resolves after mins in TIA, persists in stroke)</p>
<p class="noindent3"><b class="calibre7">Other:</b> migraine, Chiari, epilepsy, MS, tumors, drugs/meds, concussion</p>
<p class="h">Initial evaluation</p>
<p class="noindent1">• <b class="calibre7">Hx:</b> ask open-ended questions (description by Pt may be unreliable), pace of illness, episodic vs. chronic, meds, other sx of posterior circ including diplopia, dysarthria, ataxia</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbody"><b class="calibre7">Exam</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Peripheral Causes</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Central Causes</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Orthostatics</p></td>
<td class="th1"><p class="tbody">⊕ in orthostatic syncope</p></td>
<td class="th1"><p class="tbody">Typically absent</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Eye movements</p></td>
<td class="th1"><p class="tbody">Nystagmus unidirectional if present, never vertical, suppressed w/ fixation</p></td>
<td class="th1"><p class="tbody">Nystagmus bidirectional, often vertical, not suppressed w/ fixation</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Hearing</p></td>
<td class="th1"><p class="tbody">May be impaired in some peripheral causes of vertigo</p></td>
<td class="th1"><p class="tbody">Normal (rarely unilat. hearing loss in AICA-territory stroke)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Coord./gait</p></td>
<td class="th1"><p class="tbody">Normal</p></td>
<td class="th1"><p class="tbody">May reveal limb, trunk, gait ataxia</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• <b class="calibre7">HINTS testing</b> <span class="r1">(</span><span class="r2">Stroke</span> <span class="r1">2009;40:3504)</span></p>
<p class="noindent2"><b class="calibre7">H</b>ead <b class="calibre7">I</b>mpulse test: Pt fixates on examiner’s nose during rapid passive head turn of ~10–20°; presence of “catch-up saccade” supports peripheral dysfunction to side of turn</p>
<p class="noindent2"><b class="calibre7">N</b>ystagmus (see table above)</p>
<p class="noindent2"><b class="calibre7">T</b>est of <b class="calibre7">S</b>kew: vertical refixation saccade on alternating eye cover supports central cause</p>
<p class="noindent1">• <b class="calibre7">Dix-Hallpike test:</b> Pt sitting → lying back w/ 45º head tilt; elicits rotatory nystagmus after delay of secs; fatigues if repeated; ⊕ suggests BPPV w/ affected ear down</p>
<p class="noindent1">• <b class="calibre7">Supine Roll test:</b> nystagmus elicited by head turn while patient supine; when ⊕ suggests BPPV w/ affected ear down (lateral canal, 8% of cases)</p>
<p class="noindent1">• <b class="calibre7">Studies:</b> orthostatic VS, basic labs, ECG; if concerning s/s HINTS → MRI brain</p>
<p class="noindent1">• <b class="calibre7">Rx:</b> Epley for BPP; vestib. PT; anti-hist., sedative or anti-emetic, steroid for vestib. neuritis</p>
<h2 class="ct"><a id="h118" class="calibre8"></a><a id="page_9-6" class="calibre8"></a><a href="part0003.html#rh130" class="calibre8">STROKE</a></h2>
<p class="h1cr">I<small class="calibre31">SCHEMIC</small> S<small class="calibre31">TROKE</small></p>
<p class="h">Etiologies</p>
<p class="noindent1">• Embolic: artery → artery, cardioembolic (~30% due to AF; <span class="r2">NEJM</span> <span class="r1">2014;370:2478</span>), paradoxical</p>
<p class="noindent1">• Thrombotic: large vessel (atherosclerosis) vs. small vessel (“lacunar,” lipohyalinosis of small arteries, often related to smoking, HTN, hyperlipidemia, &amp; DM)</p>
<p class="noindent1">• Other: hypoperfusion, dissection, vasculopathy (vasculitis, radiation), vasospasm, hypercoag, hematologic (sickle cell, hyperviscosity), endocarditis, venous</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Timing: embolic → sudden onset; thrombotic → may have stuttering course</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Stroke Syndromes by Vascular Territory</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Artery</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Deficits</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">ICA → Ophth</p></td>
<td class="th1"><p class="tbody">Amaurosis fugax (transient monocular blindness)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">ACA</p></td>
<td class="th1"><p class="tbody">Hemiplegia (leg &gt;arm), abulia, urinary incontinence, primitive reflexes</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">MCA</p></td>
<td class="th1"><p class="tbody">Hemiplegia (face &amp; arm &gt;leg); hemianesthesia; homonymous hemianopia</p>
<p class="tbody">Aphasia if dom. hemisphere: sup. div. → expressive; inf. div → receptive</p>
<p class="tbody">Apraxia &amp; neglect if nondom. hemisphere.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">PCA</p></td>
<td class="th1"><p class="tbody">Macular-sparing homonymous hemianopia; alexia w/o agraphia</p>
<p class="tbody">Thalamic syndromes with contralateral hemisensory disturbance</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Vertebral, PICA</p></td>
<td class="th1"><p class="tbody">Wallenberg syndrome = numbness of ipsilateral face and contralateral limbs, diplopia, dysarthria, dysphagia, ipsilateral Horner’s, hiccups</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Basilar</p></td>
<td class="th1"><p class="tbody">Pupillary Δs (midbrain=dilated, pons=pinpoint), long tract signs (quadriplegia, sensory loss), CN abnl, cerebellar dysfxn. Top of basilar → ”locked in” synd.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Cerebellar</p></td>
<td class="th1"><p class="tbody">Vertigo, N/V, diplopia, dysarthria, nystagmus, ipsilateral limb ataxia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Lacunar (arterioles)</p></td>
<td class="th1"><p class="tbody">5 major syndromes: pure hemiplegia, pure hemianesthesia, ataxic hemiparesis, dysarthria + clumsy hand, mixed sensorimotor</p></td>
</tr>
</tbody>
</table>
<p class="h">Transient ischemic attack <span class="r">(TIA)</span></p>
<p class="noindent1">• Sudden deficit due to cerebral ischemia; <b class="calibre7">no stroke on imaging;</b> most resolve in &lt;1 h</p>
<p class="noindent1">• Ddx: seizure, migraine, hypoglycemia, amyloid spells, TGA, anxiety</p>
<p class="noindent1">• Risk of subsequent stroke ~2% by 1 wk <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;374:1533)</span>. Can stratify based on <b class="calibre7">ABCD<sub class="calibre10">2</sub>: A</b>ge ≥60 y (+1); <b class="calibre7">B</b>P ≥140/90 (+1); <b class="calibre7">C</b>lin features: unilat. weak. (+2), speech impair. w/o weakness (+1); <b class="calibre7">D</b>uration ≥60 (+2) or 10–59 min (+1); <b class="calibre7">D</b>M (+1)</p>
<p class="h">Physical exam</p>
<p class="noindent1">• General: murmurs, carotid &amp; subclavian bruits, peripheral emboli, endocarditis stigmata</p>
<p class="noindent1">• Neurologic exam, NIH stroke scale <span class="r1">(<a href="http://www.stroke.nih.gov/documents/NIH_Stroke_Scale_508C.pdf" class="calibre4">http://www.stroke.nih.gov/documents/NIH_Stroke_Scale_508C.pdf</a>)</span></p>
<p class="h">Acute workup</p>
<p class="noindent1">• Electrolytes, Cr (relevant for contrast); glc, CBC, coags (see exclusion criteria for lysis)</p>
<p class="noindent1">• Cardiac biomarkers, 12-lead ECG, tox screen</p>
<p class="noindent1">• <b class="calibre7">STAT CT</b> to r/o ICH prior to lysis (Se ICH ≈ MRI, CT faster). Early signs of stroke: hyperdense artery, loss of gray-white differentiation, edema, insular ribbon. CT can be nl initially, &amp; not Se for small or brainstem stroke. CTA if possible endovascular Rx.</p>
<p class="h">Acute treatment of ischemic stroke <span class="r1">(</span><span class="r2">Stroke</span><span class="r1"> 2019;50:e344;</span> <span class="r2">JAMA</span><span class="r1"> 2021;325:1088)</span></p>
<p class="noindent1">• <b class="calibre7">Thrombolysis (IV):</b> tPA 0.9 mg/kg (max 90 mg), w/ 10% as bolus over 1 min, rest over 1 h</p>
<p class="noindent2">consider if onset w/in 4.5 h, Ø contraindic. (incl. current/prior ICH; head trauma or stroke w/in 3 mo; intracranial neoplasm, AVM or aneurysm; recent intracranial/intraspinal surgery; active internal bleeding; noncompressible arterial puncture; ↑ BP; multilobar infarct; plt &lt;100k, INR &gt;1.7, on Xa inhib, PTT &gt;40, glc &lt;50)</p>
<p class="noindent2">0–3 h: 12% absolute ↑ in good neuro outcome (min/no disability), 5.8% absolute ↑ in ICH, trend toward 4% absolute ↓ mortality</p>
<p class="noindent2">3–4.5 h: 7.4% absolute ↑ in good neuro outcome, 1.8% absolute ↑ in ICH, Ø mortality benefit (nb, trial excluded patients with previous strokes + DM)</p>
<p class="noindent2">Data for tenecteplase (TNK), Rx up to 9 h or unknown timing, and for MRI imaging to guide Rx <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:1573 &amp; 379:611; 2019;380:1795;</span> <span class="r2">Lancet</span> <span class="r1">2020;396:1574)</span></p>
<p class="noindent1">• BP: lower to &lt;185/110 to consider lysis; if lyse keep &lt;180/105 × 24 h (consider IV labetalol or nicardipine), o/w permissive HTN unless &gt;220/120 or sx; if sx HoTN consider vasopressors</p>
<p class="noindent1">• Initiate ASA w/in 24–48 h; avoid anticoagulation w/in 24 h of lysis; see below for long-term Rx</p>
<p class="noindent1">• Cerebral edema → herniation: 1–5 d post large MCA or cerebellar strokes, ↑ risk in young. Elevate HOB &gt;30°; mannitol ± 23% NaCl. Hemicraniectomy ↓ mortality <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;370:1091)</span>. Neurosurgery consult in select MCA and all large cerebellar strokes.</p>
<p class="noindent1">• <b class="calibre7">Endovascular thrombectomy</b> if w/in 6 h of sx onset, pre mRS 0-1, occlusion in ICA or MCA, NIHSS ≥6, ASPECTS ≥6 (CT-based likelihood of recovery). May extend to 6–24 h if mismatch between infarct size and clinical deficits or stroke penumbra <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:11 &amp; 708)</span>.</p>
<p class="h"><a id="page_9-7" class="calibre4"></a>Workup to assess for etiology/modifiable risk factors</p>
<p class="noindent1">• Cardiac: monitor for AF (inPt and extended outPt); TTE to r/o thrombus/veg, w/ bubble study to r/o PFO/atrial septal aneurysm if suspect embolic</p>
<p class="noindent1">• Vessel imaging: CTA or MRA head/neck; carotid U/S w/ Doppler if contraindic to CTA/MRA</p>
<p class="noindent1">• Labs: lipids, HbA1c, TSH, homocysteine, Lp(a), hypercoag w/u (if &lt;65 y or cryptogenic stroke; ideally drawn before starting anticoag), ESR/CRP, blood cx if s/s systemic infection</p>
<p class="noindent1">• <b class="calibre7">MRI</b> helpful if dx of stroke unclear (esp. post circ) or to define stroke subtype, age, exact size</p>
<p class="noindent2"><i class="calibre6">DWI</i> bright/<i class="calibre6">ADC</i> dark = earliest finding in acute ischemia (~w/in mins, up to days)</p>
<p class="noindent2"><i class="calibre6">T2-FLAIR:</i> hyperintense w/in about 6 hrs, persists for wks; <i class="calibre6">PWI</i> differentiates irreversibly infarcted core vs. viable penumbra; <i class="calibre6">T</i>1<i class="calibre6"> fat-sat</i> (neck vessels) if suspicious for dissection</p>
<p class="h">Secondary stroke prevention <span class="r1">(</span><span class="r2">Stroke</span><span class="r1"> 2021;52:e364)</span></p>
<p class="noindent1">• <b class="calibre7">Antiplatelet therapy:</b> different agents likely have similar efficacy</p>
<p class="noindent2"><b class="calibre7">ASA</b> ↓ death &amp; repeat stroke; equal to warfarin in nonembolic stroke <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2001;345:1444)</span></p>
<p class="noindent2"><b class="calibre7">clopidogrel:</b> marginally superior to ASA, slightly ↑ ICH <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">1996;348:1329)</span></p>
<p class="noindent2"><b class="calibre7">P2Y<sub class="calibre10">1</sub><sub class="calibre10">2</sub></b> (clopi or ticag) +<b class="calibre7"> ASA</b> (vs. ASA alone): Rx for 1–3 mos in <i class="calibre6">minor</i> strokes or TIA w/ high ABCD<sup class="calibre19">2</sup> → ↓ risk of ischemic stroke, ↑ ICH <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;379:215 &amp; 2020;383:207)</span>. Rx for 90 d if stroke due to intracranial athero <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2011;365:993)</span>.</p>
<p class="noindent1">• <b class="calibre7">Anticoagulation (AC):</b> consider for AF (qv), cardiac/paradoxical emboli (except bacterial endocard); large extra-dural dissections; hypercoag; bridge to CEA in sx carotid stenosis</p>
<p class="noindent2"><b class="calibre7">Hold off on AC</b> in large strokes for ~2–4 wk given risk of hemorrhagic conversion</p>
<p class="noindent1">• Long-term SBP target &lt;130/80 mmHg</p>
<p class="noindent1">• ↓ LDL-C (&lt;&lt; 70 mg/dL): ↓ recurrence w/ statin PCSK9i added to statin <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;376:1713)</span></p>
<p class="noindent1">• <b class="calibre7">Carotid revascularization</b> <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;369:1143)</span></p>
<p class="noindent2"><b class="calibre7">CEA</b> (<i class="calibre6">if</i> surgical morbidity &amp; mortality ≤6%) indicated for:</p>
<p class="noindent3"><i class="calibre6">sx stenosis</i> 70–99% (benefit ↑ for males, &gt;75 y, ≤2 wk from stroke) → 65% ↓ RR of repeat stroke, slight benefit for 50–69% stenosis <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">1991;325:445;</span> <span class="r2">Lancet</span> <span class="r1">2004;363:915)</span></p>
<p class="noindent3"><i class="calibre6">asx stenosis</i> 70–90%, &lt;79 y: 50% ↓ RR of repeat stroke <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2010;376:1074)</span></p>
<p class="noindent2"><b class="calibre7">Stenting:</b> c/w CEA, ↑ periprocedural stroke (esp. in elderly) &amp; ↓ MI (but many asx); subseq. ≈ rates of fatal or disabling stroke, but ↑ non-disabling stroke <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2021;398:1065)</span></p>
<p class="h">Patent foramen ovale <span class="r">(PFO; in ~25% of population)</span> <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2005;353:2361)</span></p>
<p class="noindent1">• ↑ stroke risk: ≥4 mm separation, R→L shunting at rest, ↑ septal mobility, atrial septal aneurysm</p>
<p class="noindent1">• Risk scores assess likelihood stroke related to PFO. RoPE score: age (+1 for each decade &lt;70); cortical stroke on imaging (+1); HTN, DM, h/o stroke/TIA, smoker (+1 for each <i class="calibre6">absent</i> risk factor). PASCAL classification also includes large shunt or atrial septal aneurysm.</p>
<p class="noindent1">• If PFO &amp; stroke/TIA: no benefit of warfarin vs. ASA, but consider if high risk for or has DVT/PE</p>
<p class="noindent1">• Closure ↓ recurrence by ≥50%, with magnitude of benefit dependent on risk classification (RoPE ≥7 or PASCAL classification of possible or probable) <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2021;326:2277)</span></p>
<p class="h1cr">I<small class="calibre31">NTRACRANIAL</small> H<small class="calibre31">EMORRHAGE</small> (ICH)</p>
<p class="h">Classification by location</p>
<p class="noindent1">• Hemorrhagic strokes: intraparenchymal hemorrhage (IPH) &amp; subarachnoid hemorrhage (SAH)</p>
<p class="noindent1">• Other ICH: epidural hematoma (EDH) &amp; subdural hematoma (SDH)</p>
<p class="h">Etiologies</p>
<p class="noindent1">• AVM, aneurysm, cerebral venous sinus thrombosis → IPH or SAH</p>
<p class="noindent1">• HTN (basal ganglia, cerebellum, brainstem), cerebral amyloid (lobar), tumor (esp. w/ melanoma, renal cell CA, chorio-CA, thyroid CA) → IPH</p>
<p class="noindent1">• Trauma → all locations (nb, IPH or SAH caused by trauma technically not a stroke)</p>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2017;389:655 &amp;</span> <span class="r2">NEJM</span><span class="r1"> 2017;377:257)</span></p>
<p class="noindent1">• ↓ consciousness, N/V, HA, progressive focal neurologic deficits</p>
<p class="noindent1">• <i class="calibre6">SAH:</i> thunderclap HA, onset w/ exertion; nuchal pain/rigidity; LOC. <i class="calibre6">EDH:</i> initial lucid interval.</p>
<p class="h">Workup <span class="r1">(</span><span class="r2">Acad Emerg Med</span> <span class="r1">2016;23:963)</span></p>
<p class="noindent1">• <b class="calibre7">STAT CT brain, angio (CT-A or conventional) if suspicious for vascular source</b></p>
<p class="noindent1">• ? LP for xanthochromia if no evid of ICH on CT (although ⊖ LR 0.01) &amp; suspicious for SAH</p>
<p class="noindent1">• Coags (PT, PTT, INR)</p>
<p class="h">Management <span class="r1">(</span><span class="r2">Crit Care Med</span> <span class="r1">2016;44:2251;</span> <span class="r2">JAMA</span><span class="r1"> 2019;321:1295)</span></p>
<p class="noindent1">• Reverse coagulopathy, INR &lt;1.4. Plt &gt;100k, no need for plt tfn if on antiplt Rx (? if ↑ ICH), DDAVP if uremic. 2–3 mo after recovers, can restart antiplt mono Rx <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2019;393:2013)</span>.</p>
<p class="noindent1">• BP control w/ art line, nicardipine or labetalol gtt. SBP goal &lt;140 for 1<sup class="calibre19">st</sup> 24 h, then &lt;160 <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;368:2355 &amp; 2016;375:1033)</span>, though BP goals controversial <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;375:1033)</span></p>
<p class="noindent1">• SAH: endovasc coiling vs. surg clipping (depends on location, comorbid.; <span class="r2">Lancet</span> <span class="r1">2015;385:691</span>) of aneurysm/AVM; nimodipine to ↓ risk of vasospasm (monitor w/ TCDs), seizure Ppx</p>
<p class="noindent1">• Surg evac: EDH; SDH if &gt;1 cm or rapid ↑, Rx-resistant epilepsy; IPH: no obvious benefit</p>
<p class="noindent1">• Venous sinus thrombosis: start anticoagulation, manage ↑ ICP and seizures as needed</p>
<h2 class="ct"><a id="h119" class="calibre8"></a><a id="page_9-8" class="calibre8"></a><a href="part0003.html#rh131" class="calibre8">WEAKNESS &amp; NEUROMUSCULAR DYSFUNCTION</a></h2>
<p class="imaget"><img src="../images/00108.jpeg" alt="" class="calibre5"/></p>
<p class="h1cr">P<small class="calibre31">ERIPHERAL</small> N<small class="calibre31">EUROPATHIES</small></p>
<p class="h">Etiologies based on presentation</p>
<p class="noindent1">• <b class="calibre7">Mononeuropathy</b> (1 nerve): <i class="calibre6">acute</i> → trauma; <i class="calibre6">chronic</i> → entrapment, compression, DM, Lyme. Common: median nerve (carpal tunnel); ulnar (elbow or wrist); radial (spiral groove); com. peroneal (fibular head w/ leg crossing); lat. femoral cutan. (inguinal lig)</p>
<p class="noindent1">• <b class="calibre7">Mononeuropathy multiplex</b> (axonal loss of multiple, noncontig. nerves): vasculitic synd. (eg, PAN, EGPA, GPA, SLE, RA, Sjögren’s, cryo, HCV), DM, Lyme, HIV, leprosy, hereditary neurop. w/ pressure palsies, infiltrative (sarcoid, lymphoma, leukemia)</p>
<p class="noindent1">• <b class="calibre7">Polyneuropathy</b> (multiple symmetric nerves, generally length dependent): 30% idiopathic;</p>
<p class="noindent2"><i class="calibre6">W/ autonomic features:</i> DM, EtOH, paraneoplastic, B<sub class="calibre10">12</sub> def, amyloid, chemo, 1° dysauto</p>
<p class="noindent2"><i class="calibre6">Painful (small fiber nerves):</i> DM, EtOH, amyloid, chemo, sarcoid, heavy metals, porphyria</p>
<p class="noindent2"><i class="calibre6">Demyelinating.</i> <span class="underline">Acute</span>: AIDP (Guillain-Barré), diphtheria. <span class="underline">Subacute</span>: meds (taxanes), paraneoplastic. <span class="underline">Chronic</span>: idiopathic, DM, CIDP, anti-MAG, HIV, hypothyroidism, toxins, paraproteinemia, hereditary (eg, CMT).</p>
<p class="noindent2"><i class="calibre6">Axonal.</i> <span class="underline">Acute</span>: acute motor axonal neuropathy, porphyria, vasculitis, uremia, critical illness. <span class="underline">Subacute</span>: EtOH, sepsis, paraneoplastic, meds (cisplatin, paclitaxel, vincristine, INH, ddI, amio). <span class="underline">Chronic</span>: DM, uremia, lead, arsenic, HIV, paraproteinemia, B<sub class="calibre10">1</sub><sub class="calibre10">2</sub> defic.</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Weakness, fasciculations, cramps, numbness, dysesthesias (burning/tingling), allodynia</p>
<p class="noindent1">• ↑ Autonomic dysfxn (orthostasis, constipation, urinary retention, impotence, abnl sweating)</p>
<p class="noindent1">• Depressed or absent DTRs (may be normal in small fiber neuropathy)</p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• Distal symmetric polyneuropathy: CBC, lytes, BUN/Cr, Hb<sub class="calibre10">A1C</sub>, B<sub class="calibre10">12</sub>, ESR, SPEP + IF</p>
<p class="noindent1">• EMG/NCS (often no change in 1<sup class="calibre19">st</sup> 10–14 d or in small-fiber neuropathy)</p>
<p class="noindent1">• Based on H&amp;P: LFTs, celiac Abs, ANA, anti-Ro/La, HIV, Cu, Lyme, RPR, UA, UPEP+IF, ACE, ANCA, heavy metals, LP (AIDP/CIDP), cryo, paraneoplastic Abs, genetic testing. Autonomic testing/skin bx (small fiber), nerve bx (mononeuropathy multiplex), fat pad bx (amyloid).</p>
<p class="noindent1">• MRI if possible radiculopathy or plexopathy (after EMG)</p>
<p class="h">Pharmacologic treatment of neuropathic pain <span class="r1">(</span><span class="r2">Lancet Neurol</span> <span class="r1">2015;14:162)</span></p>
<p class="noindent1">• Gabapentin, pregabalin, TCAs (nortriptyline, amitriptyline), SNRIs (duloxetine, venlafaxine)</p>
<p class="noindent1">• 2<sup class="calibre19">nd</sup> line: tramadol, topicals (lido, capsaicin); 3<sup class="calibre19">rd</sup> line: nerve block, botulinum toxin A</p>
<p class="h1cr">G<small class="calibre31">UILLAIN</small>-B<small class="calibre31">ARRE</small> S<small class="calibre31">YNDROME</small> (GBS)</p>
<p class="h">Definition &amp; epidemiology <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2021;397:1214)</span></p>
<p class="noindent1">• AIDP (60–80%); acute motor axonal neuropathy (AMAN; 7–30%; a/w anti-GM1, anti-GD1a Abs; worse prognosis); Miller Fisher synd. (ophthalmoplegia &amp; ataxia; a/w anti-GQ1b Ab)</p>
<p class="noindent1">• Incidence 1–2 per 100,000; most common acute/subacute paralysis</p>
<p class="noindent1">• Precipitants in 60%: viral illness (influenza, CMV, EBV, HIV, Zika, COVID-19), URI (<i class="calibre6">Mycoplasma</i>), gastroenteritis (<i class="calibre6">Campylobacter</i>), Lyme, immunizations, immune checkpoint inhibitors, surgery</p>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">Nat Rev Neurol</span> <span class="r1">2019;15:671)</span></p>
<p class="noindent1">• Pain (55–90%), distal sensory dysesthesias &amp; numbness often 1<sup class="calibre19">st</sup> sx, back pain common</p>
<p class="noindent1">• Progressive symmetric paralysis in legs and arms over hrs to days; plateau in 1–4 wk</p>
<p class="noindent1">• Hypoactive then absent reflexes. &lt;10% w/ reflexes on presentation, but all develop hypo/areflexia during course. Minority of AMAN w/ preserved reflexes throughout.</p>
<p class="noindent1">• Resp failure requiring mech vent occurs in 25%; autonomic instability &amp; arrhythmias in 60%</p>
<p class="h">Diagnostic studies <span class="r">(results may be normal in first several days)</span></p>
<p class="noindent1">• LP: albuminocytologic dissociation = ↑ protein w/o pleocytosis (&lt;10 WBCs) seen in up to 64% of Pts. ↑ protein in ½ in 1<sup class="calibre19">st</sup> wk, ¾ by 3<sup class="calibre19">rd</sup> wk of sx. Unlikely to be GBS if WBC &gt;50</p>
<p class="noindent1">• EMG/NCS: ↓ conduction velocity, conduction block, abnl F-waves; can be nl in 1<sup class="calibre19">st</sup> 2 wk</p>
<p class="noindent1"><a id="page_9-9" class="calibre4"></a>• FVC &amp; NIF: to assess for risk of resp. failure (cannot rely on P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> or S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> alone)</p>
<p class="h">Treatment</p>
<p class="noindent1">• <b class="calibre7">Plasma exchange or IVIg of equal efficacy</b> <span class="r1">(</span><span class="r2">Neuro</span> <span class="r1">2012;78:1009)</span>; steroids not beneficial</p>
<p class="noindent1">• Supportive care with monitoring in ICU setting if rapid progression or resp. failure</p>
<p class="noindent1">• Watch for autonomic dysfunction: labile BP, dysrhythmias, urinary retention, ileus</p>
<p class="noindent1">• Erasmus GBS outcome score can help w/ prognostication <span class="r1">(</span><span class="r2">Lancet Neurol</span> <span class="r1">2007;6:589)</span>. Most recover near baseline in 1 y; 3–5% mortality. Residual deficits: pain, fatigue.</p>
<p class="h1cr">M<small class="calibre31">YASTHENIA</small> G<small class="calibre31">RAVIS</small> (MG)</p>
<p class="h">Definition &amp; epidemiology <span class="r1">(</span><span class="r2">Lancet Neurol</span> <span class="r1">2015;14:1023;</span> <span class="r2">NEJM</span><span class="r1"> 2016;375:2570)</span></p>
<p class="noindent1">• Autoimmune disorder with Ab against acetylcholine receptor (AChR, 80%), muscle-specific kinase (MusK, 4%), lipoprotein-related protein 4 (LRP4, 2%), or other NMJ proteins</p>
<p class="noindent1">• Prevalence: 150–250 per million; all ages, peak incidence 20s–30s (F), 60s–70s (M)</p>
<p class="noindent1">• 15% of AchR MG a/w thymoma; 30% of pts w/ thymoma develop AchR MG</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Fluctuating weakness w/ <i class="calibre6">fatigability</i> (worse w/ repetitive use, relieved by rest)</p>
<p class="noindent1">• Cranial muscles involved early → 60% present initially w/ ocular sx (ptosis, diplopia); 15% confined to ocular sx; 15% w/ bulbar (difficulty chewing, dysarthria, dysphagia)</p>
<p class="noindent1">• Limb weakness proximal &gt;distal; DTRs preserved; minimal/no atrophy</p>
<p class="noindent1">• MusK MG (F &gt;&gt;M): more severe limb/facial/bulbar weakness, muscle atrophy</p>
<p class="noindent1">• Exacerb. triggers: URI, surgery, preg/postpartum, meds (eg, Mg, AG, macrolides, FQ, procainamide, phenytoin, D-penicillamine, β-blocker). Prednisone can <i class="calibre6">worsen</i> sx acutely.</p>
<p class="noindent1">• Myasthenic crisis = sx exacerbation, risk of respiratory compromise</p>
<p class="noindent1">• Cholinergic crisis = excessive Rx with anticholinesterases: salivation, cramping, diarrhea</p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• Bedside: ptosis, worse after &gt;45 sec of sustained upgaze; improved with ice pack over eyes for 2–5 min (Se 77%, Sp 98%), ophthalmoplegia, weakness</p>
<p class="noindent1">• Neostigmine test: temporary ↑ strength; false ⊕ &amp; ⊖ occur; premedicate w/ atropine</p>
<p class="noindent1">• EMG: ↓ response with repetitive nerve stimulation (vs. ↑ response in Lambert-Eaton)</p>
<p class="noindent1">• Anti-AChR Ab (Se 80%, 50% if ocular disease only, Sp &gt;90%); muscle specific receptor tyrosine kinase (MuSK) Ab; AchR modulating Ab</p>
<p class="noindent1">• CT or MRI of thorax to evaluate thymus (65% hyperplasia, 10% thymoma)</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Neurology</span><span class="r1"> 2021;96:114)</span></p>
<p class="noindent1">• Thymectomy if thymoma and in Ab ⊕ Pts w/o thymoma <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;375:511)</span></p>
<p class="noindent1">• Cholinesterase inhibitor (eg, pyridostigmine) is most rapid acting (30–60 min). Less effective for MusK MG. Side effects: cholinergic stim (brady, diarrhea, drooling).</p>
<p class="noindent1">• Immunosuppression: prednisone (benefit in wks; don’t start during crisis) + steroid-sparing agent: AZA (benefit in 6–15 mo), MMF. Refractory: rituximab, MTZ, eculizumab.</p>
<p class="noindent1">• Myasthenic crisis: treat precipitant; d/c cholinesterase inhibitor if suspect cholinergic crisis. IVIg or plasmapheresis; if no response, high-dose glucocorticoids (monitor for initial worsening). ICU if rapid or severe (follow FVC, NIF).</p>
<p class="h1cr">M<small class="calibre31">YOPATHIES</small></p>
<p class="h">Etiologies <span class="r1">(</span><span class="r2">Front Neurol</span> <span class="r1">2011;2:49)</span></p>
<p class="noindent1">• Hereditary: Duchenne, Becker, limb-girdle, myotonic, metabolic, mitochondrial</p>
<p class="noindent1">• Endocrine: hypothyroidism, hyperparathyroidism, Cushing syndrome</p>
<p class="noindent1">• Toxic: statins, fibrates, steroids, zidovudine, EtOH, cocaine, colchicine, penicillamine</p>
<p class="noindent1">• Infectious: HIV, HTLV-1, trichinosis, toxoplasmosis, COVID-19</p>
<p class="noindent1">• Inflammatory: polymyositis, dermatomyositis, inclusion body myositis, anti-HMGCR</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Progressive or episodic weakness (not fatigue)</p>
<p class="noindent1">• Weakness most often symmetric, proximal &gt;distal (stairs, rising from sitting, etc.)</p>
<p class="noindent1">• ↑ Myalgias (though not prominent or frequent), cramps, myotonia (impaired relaxation)</p>
<p class="noindent1">• May develop either pseudohypertrophy (dystrophies) or mild muscle atrophy</p>
<p class="noindent1">• Assoc. organ dysfxn: cardiac (arrhythmia, CHF), pulmonary (ILD), dysmorphic features</p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• CK, aldolase, LDH, electrolytes, ALT/AST, PTH, TSH, ESR, HIV</p>
<p class="noindent1">• Autoantibodies: ANA, RF, anti-Jo1, antisynthetase, anti-Mi-2, anti-SRP, anti-HMGCR, 5TN1CA (in inclusion body myositis)</p>
<p class="noindent1">• EMG/NCS: low-amplitude, polyphasic units w/ early recruitment, ↑ fibrillation potentials</p>
<p class="noindent1">• Muscle biopsy, molecular genetic testing (where indicated)</p>
<p class="noindent1">• Age-appropriate cancer screening if polymyositis or dermatomyositis suspected</p>
<h2 class="ct"><a id="h120" class="calibre8"></a><a id="page_9-10" class="calibre8"></a><a href="part0003.html#rh132" class="calibre8">HEADACHE</a></h2>
<p class="h">Primary headache syndromes <span class="r1">(</span><span class="r2">Cephalgia</span><span class="r1"> 2018;38:1)</span></p>
<p class="noindent1">• <b class="calibre7">Tension-type:</b> bilateral, pressure-like pain of mild–mod intensity, not throbbing or aggravated by physical activity. A/w photophobia or phonophobia, not N/V. Freq a/w myofascial sensitivity in neck/head. Triggers: stress, sleep deprivation, dehydration, hunger. Episodic HA Rx: NSAIDs, acetaminophen (risk of med overuse HA); chronic HA Rx: TCAs.</p>
<p class="noindent1">• <b class="calibre7">Cluster HA</b> and other trigeminal autonomic cephalalgias (TACs) <span class="r1">(</span><span class="r2">Continuum</span> <span class="r1">2018;24:1137)</span></p>
<p class="noindent2">Characterized by unilateral headache a/w ipsilateral autonomic sx (rhinorrhea, red/tearing eye, miosis, ptosis, lid edema, sweating), subtypes differentiated by timing.</p>
<p class="noindent2"><i class="calibre6">Cluster:</i> ♂ &gt;♀, unilateral pain w/ autonomic sx &amp; restlessness; attacks 15 min–3 h, up to 8/d (circadian). Rx: high-flow O<sub class="calibre10">2</sub> (12–15 L/min), sumatriptan. Ppx: CCB (verapamil).</p>
<p class="noindent2"><i class="calibre6">Paroxysmal hemicrania:</i> similar to cluster, but ♀ &gt;♂, attacks 2–30 min. Rx: indomethacin.</p>
<p class="noindent2"><i class="calibre6">Hemicrania continua:</i> ♀ &gt;♂, ice pick–like pain lasting &gt;3 mo. Rx: indomethacin.</p>
<p class="noindent2"><i class="calibre6">Short-lasting unilateral neuralgiform HA</i> (SUNA/SUNCT)<i class="calibre6">:</i> ♂ &gt;♀, excruciating, stabbing, electrical pain, 5 sec–4 min, up to 200×/d. Rx: lamotrigine, gabapentin, topiramate.</p>
<p class="noindent1">• <b class="calibre7">Migraine:</b> <i class="calibre6">see below</i></p>
<p class="h">Secondary causes of headaches <span class="r1">(</span><span class="r2">Neurology</span><span class="r1"> 2019;92:134)</span></p>
<p class="noindent1">• Traumatic: post-concussion, SAH, SDH, postcraniotomy</p>
<p class="noindent1">• ↑ ICP: mass (tumor, abscess, vascular malformations, ICH), hydrocephalus, idiopathic intracranial hypertension (pseudotumor cerebri), altitude-associated cerebral edema</p>
<p class="noindent1">• ↓ ICP: post-LP headache, CSF leak/dural tear, overshunting</p>
<p class="noindent1">• Vascular: stroke (esp. posterior circ), dissection, vasculitis (incl. temporal arteritis), reversible cerebral vasoconstriction syndrome (RCVS), ICH, venous sinus thrombosis</p>
<p class="noindent1">• Meningeal irritation: meningitis, SAH</p>
<p class="noindent1">• Extracranial: sinusitis, TMJ syndrome, glaucoma</p>
<p class="noindent1">• Systemic: hypoxia (OSA), hypercapnia, dialysis, HTN, cardiac cephalalgia, hypoglycemia, ↓ TSH, pheo, medication overuse (analgesics), withdrawal (caffeine, opioids, estrogen)</p>
<p class="h">Clinical evaluation <span class="r1">(</span><span class="r2">Neurology</span><span class="r1"> 2019;92:134 &amp;</span> <span class="r2">JAMA</span><span class="r1"> 2021;325:1874)</span></p>
<p class="noindent1">• Hx: onset (sudden vs. gradual), quality, evolution (progressive), severity, location, duration, triggers, alleviating factors, positional, hormonal (menstruation), preceding trauma, assoc. sx (visual Δs, “floaters,” N/V, photophobia, focal neuro sx), meds (new, analgesics), substance abuse (opioids, caffeine), personal/family hx of HA; neoplasm, preg</p>
<p class="noindent1">• General and neurologic exam (including funduscopic exam, visual fields). Headache diary.</p>
<p class="noindent1">• <b class="calibre7">Warning signs (should prompt neuroimaging)</b></p>
<p class="noindent2"><i class="calibre6">Explosive onset</i> (vasc); “worst HA of life” (SAH, RCVS); <i class="calibre6">meningismus</i> (SAH, infxn)</p>
<p class="noindent2"><i class="calibre6">Positional:</i> lying &gt;standing (↑ ICP); <i class="calibre6">N/V</i> (↑ ICP; migraines); coughing/bearing down (↑ ICP)</p>
<p class="noindent2"><i class="calibre6">Visual sx:</i> diplopia, blurring, ↓ acuity (GCA, glaucoma, ↑ ICP); <i class="calibre6">eye pain</i> (glaucoma, trigeminal autonomic cephalalgia, optic neuritis)</p>
<p class="noindent2"><i class="calibre6">Abnl exam</i> (struct. lesion, poss. in migraine); ↓ <i class="calibre6">consciousness</i>; systemic sx (fever)</p>
<p class="noindent2"><i class="calibre6">Age</i> &gt;<i class="calibre6">65 y; immunosuppression</i> (CNS infections, PRES)</p>
<p class="noindent1">• Imaging: CT or MRI; consider CTA (beading in vasculitis/RCVS/vasospasm), CTV/MRV</p>
<p class="noindent1">• LP if ? SAH (✓ for xanthochromia), idiopathic intracranial HTN (✓opening press); image first!</p>
<p class="h1cr">M<small class="calibre31">IGRAINE</small> <span class="r3">(</span><span class="r4">NEJM</span><span class="r3"> 2017;377:553)</span></p>
<p class="h">Definition &amp; clinical manifestations <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2018;391:1315 &amp;</span> <span class="r2">Continuum</span><span class="r1"> 2021;27:586)</span></p>
<p class="noindent1">• <b class="calibre7">Epidemiology:</b> affects 15% of women and 6% of men; onset usually by 30 y</p>
<p class="noindent1">• <b class="calibre7">Migraine w/o aura</b> (most common): ≥5 attacks lasting 4–72 h with both (a) N/V <i class="calibre6">or</i> photophobia &amp; phonophobia, and (b) ≥2 of following: unilateral, pulsating, mod–severe intensity, or aggravated by routine activity</p>
<p class="noindent1">• <b class="calibre7">Migraine w/ aura:</b> ≥2 attacks w/: (a) aura defined as ≥1 fully reversible sx: visual Δs (flickering spots, visual loss), sensory sx (paresthesias, numbness), speech disturbance; <i class="calibre6">and</i> (b) unilateral progression of sx over ≥5 but ≤60 min; <i class="calibre6">and</i> (c) HA w/in 60 min of aura</p>
<p class="noindent1">• Aura may occur w/o HA (“acephalgic migraine”), must r/o TIA/stroke (typically rapid onset)</p>
<p class="noindent1">• If motor weakness, consider <b class="calibre7">sporadic or familial hemiplegic migraine</b>: aura of reversible motor weakness (up to 24 h), a/w CACNA1A, ATP1A2, or SCN1A mutations</p>
<p class="noindent1">• Precipitants: stress, foods (cheese, chocolate, MSG), fatigue, EtOH, menses, exercise</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2021;397:1505 &amp;</span> <span class="r2">Continuum</span><span class="r1"> 2021;27:613)</span></p>
<p class="noindent1">• Abortive Rx: 5-HT<sub class="calibre10">1</sub> agonists (triptans) effective if given early in migraine attack; contraindicated if motor aura, CAD, prior stroke. Also consider acetaminophen, caffeine, NSAIDs (ketorolac), steroids, Mg, metoclopramide, prochlorperazine, valproate, dihydroergotamine (caution if CAD, recent triptan use). <i class="calibre6">Avoid butalbital, opioids.</i></p>
<p class="noindent1">• Prophylaxis: AEDs (topiramate, VPA), β-blockers (propranolol first-line), TCAs (amitriptyline), Mg, B2, botox, anti-CGRP, &amp; receptor mAbs <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2021;397:51)</span></p>
<h2 class="ct"><a id="h121" class="calibre8"></a><a id="page_9-11" class="calibre8"></a><a href="part0003.html#rh133" class="calibre8">BACK AND SPINAL CORD DISEASE</a></h2>
<p class="h">Differential diagnosis of back pain</p>
<p class="noindent1">• <b class="calibre7">Musculoskeletal:</b> involving spine (vertebra, facet joints), paraspinal muscles &amp; ligaments, sacroiliac joint, or hip joint. Spondylolisthesis, vertebral fx, OA, inflam. spondyloarthritis (qv), musculoligamentous “strain,” myofascial pain syndrome, trochanteric bursitis.</p>
<p class="noindent1">• <b class="calibre7">Spinal cord</b> (myelopathy)<b class="calibre7">/nerve root</b> (radiculopathy):</p>
<p class="noindent2">Degenerative/traumatic: disc herniation, foraminal or lumbar stenosis, spondylolisthesis</p>
<p class="noindent2">Neoplastic: lung, breast, prostate, RCC, thyroid, colon, multiple myeloma, lymphoma</p>
<p class="noindent2">Infectious: osteomyelitis/discitis, epidural abscess, zoster, Lyme, CMV, HIV, spinal TB</p>
<p class="noindent2">Vascular: spinal cord ischemia, dural AV fistula</p>
<p class="noindent1">• <b class="calibre7">Referred pain from visceral disease:</b></p>
<p class="noindent2">GI: PUD, cholelithiasis, pancreatitis, pancreatic cancer</p>
<p class="noindent2">GU: pyelonephritis, nephrolithiasis, uterine or ovarian cancer, salpingitis</p>
<p class="noindent2">Vascular: aortic dissection, leaking aortic aneurysm</p>
<p class="h">Initial evaluation <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2017;389:736 &amp;</span> <span class="r2">Continuum</span><span class="r1"> 2021;27:12)</span></p>
<p class="noindent1">• <b class="calibre7">History:</b> location, timing (acute/subacute/chronic), worse w/ Valsalva, radiation, trauma, wt loss, cancer, fever, immunocompromised, IVDU, neurologic sx, saddle anesthesia, Lhermitte phenomenon, bowel/bladder/sexual sx (retention, incontinence)</p>
<p class="noindent1">• <b class="calibre7">General physical exam:</b> local tenderness, ROM, signs of infection or malignancy; paraspinal tenderness or spasm in musculoskeletal strain</p>
<p class="noindent1">• <b class="calibre7">Signs of radiculopathy</b> (sharp/lancinating pain radiating into limb):</p>
<p class="noindent2"><i class="calibre6">Spurling sign</i> (cervical radiculopathy): radicular pain w/ downward force to extended &amp; ipsilaterally rotated head; 30% Se, 93% Sp</p>
<p class="noindent2"><i class="calibre6">Straight leg raise</i> (sciatica or lumbosacral radiculopathy): radicular pain at 30–70°; ipsilateral: 92% Se, 28% Sp; crossed (contralateral leg raised): 28% Se, 90% Sp</p>
<p class="noindent2"><i class="calibre6">Patrick/FABER test</i> (SI joint synd): severe pain on hip ext rotation; 70% Se, 100% Sp</p>
<p class="noindent2"><i class="calibre6">Neurogenic claudication</i> in lumbar stenosis (see table on next page)</p>
<p class="noindent1">• <b class="calibre7">Neuro exam:</b> full motor (incl. sphincter tone); gait; sensory (temp/pain, position, vibration; ↑ perineal; ? dermatomal); reflexes incl. bulbocavernous, anal wink (S4), cremasteric (L2)</p>
<p class="noindent1">• <b class="calibre7">Red flags:</b> acute change (pain, weakness), upper motor neuron signs (hyperreflexia, upgoing toes), cauda equina or conus medullaris syndromes (saddle anesthesia, bowel/bladder or sexual dysfunction, reduced rectal tone, loss of sacral reflexes), dyspnea when flat (C3–C5), pain at rest or at night</p>
<p class="noindent1">• <b class="calibre7">Laboratory</b> (depending on suspicion): CBC w/ diff, ESR/CRP, Ca, PO<sub class="calibre10">4</sub>, CSF, BCx</p>
<p class="noindent1">• <b class="calibre7">Neuroimaging:</b> low yield if nonradiating pain, high false ⊕ rate (incidental spondylosis); depending on suspicion: X-rays, CT or CT myelography, MRI, bone scan</p>
<p class="noindent1">• <b class="calibre7">EMG/NCS:</b> may be useful to distinguish root/plexopathies from peripheral neuropathies</p>
<p class="h1cr">S<small class="calibre31">PINAL</small> C<small class="calibre31">ORD</small> C<small class="calibre31">OMPRESSION</small></p>
<p class="h">Clinical features <span class="r1">(</span><span class="r2">Continuum</span><span class="r1"> 2021;27:163)</span></p>
<p class="noindent1">• Etiologies: <b class="calibre7">tumor</b> (vertebral mets, intradural meningioma/neurofibroma), <b class="calibre7">epidural abscess/ hematoma</b>, vascular malformation (dural AV fistula), degen. dis. (spondylosis), trauma</p>
<p class="noindent1">• Acute: flaccid paraparesis and absent reflexes (“spinal shock”)</p>
<p class="noindent1">• Subacute–chronic: spastic paraparesis and hyperreflexia (upgoing toes ± ankle clonus)</p>
<p class="noindent1">• Posterior column dysfunction in legs (loss of vibratory and/or proprioceptive sense)</p>
<p class="noindent1">• Sensory loss below level of lesion (truncal level ↑ bilateral leg sx is clue for cord process)</p>
<p class="h">Evaluation &amp; treatment</p>
<p class="noindent1">• Empiric spine immobilization (collar, board) for all trauma patients</p>
<p class="noindent1">• STAT MRI (at and above clinical spinal level, with gadolinium) or CT myelogram</p>
<p class="noindent1">• Emergent neurosurgical and/or neurology consultation. Urgent radiation therapy ↑ surgery for compression if due to metastatic disease <span class="r1">(</span><span class="r2">Lancet Oncol</span> <span class="r1">2017;18:e720)</span>.</p>
<p class="noindent1">• Empiric broad-spectrum antibiotics ± surgery if c/f epidural abscess</p>
<p class="noindent1">• High-dose steroids depending on cause:</p>
<p class="noindent2">Tumor: dexamethasone 16 mg/d IV (usually 4 mg q6 h) with slow taper over wks</p>
<p class="noindent2">Trauma: methylprednisolone 30 mg/kg IV over 15 min then 5.4 mg/kg/h × 24 h (if started w/in 3 h of injury) or × 48 h (if started 3–8 h after injury) <span class="r1">(</span><span class="r2">Cochrane</span> <span class="r1">2012:CD001046)</span></p>
<p class="h1cr">N<small class="calibre31">ERVE</small> R<small class="calibre31">OOT</small> C<small class="calibre31">OMPRESSION</small></p>
<p class="h">Clinical features <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2015;372:1240 &amp;</span> <span class="r2">Continuum</span><span class="r1"> 2021;27:163)</span></p>
<p class="noindent1">• Radicular pain aggravated by activity (esp. bending, straining, coughing), relieved by lying</p>
<p class="noindent1">• Sciatica = radicular pain radiating from buttocks down lateral aspect of leg, often to knee or lateral calf ± numbness and paresthesias radiating to lateral foot. Caused by compression of nerve roots, plexus, or sciatic nerve.</p>
<p class="h"><a id="page_9-12" class="calibre4"></a>Pathophysiology</p>
<p class="noindent1">• &lt;65 y: 90% from disc herniation. ≥65 y also w/ more degenerative contributors: ligamentous hypertrophy, osteophyte formation, facet arthropathy, neural foraminal narrowing</p>
<p class="noindent1">• Spinal stenosis: central canal narrowing → root compression via direct impingement, CSF flow obstruction, vascular compromise</p>
<p class="imaget"><img src="../images/00109.jpeg" alt="" class="calibre5"/></p>
<p class="tfn">Nb, lumbar disc protrusion tends to compress the nerve root that exits 1 vertebral level below the protrusion.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre20"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Neurogenic vs. Vascular Claudication</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Features</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Neurogenic Claudication</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Vascular Claudication</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Cause</p></td>
<td class="th1"><p class="tbodyc">Lumbar spinal stenosis (with nerve root compression)</p></td>
<td class="th1"><p class="tbodyc">Peripheral artery disease</p>
<p class="tbodyc">(with limb ischemia)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Pain</p></td>
<td class="th1"><p class="tbodyc">Radicular back/buttock pain</p>
<p class="tbodyc">Radiating down legs</p></td>
<td class="th1"><p class="tbodyc">Cramping leg pain</p>
<p class="tbodyc">Mostly in calves; radiating up legs</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Worse with</p></td>
<td class="th1"><p class="tbodyc">Walking &amp; standing</p>
<p class="tbodyc">Hyperextension/lying prone</p></td>
<td class="th1"><p class="tbodyc">Walking</p>
<p class="tbodyc">Biking</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Better with</p></td>
<td class="th1"><p class="tbodyc">Bending forward, sitting</p></td>
<td class="th1"><p class="tbodyc">Rest (standing or sitting)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Other sx</p></td>
<td class="th1"><p class="tbodyc">Numbness/paresthesias</p></td>
<td class="th1"><p class="tbodyc">Pale, cool extremity</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Exam</p></td>
<td class="th1"><p class="tbodyc">± Focal weakness, ↓ reflexes</p>
<p class="tbodyc">↓ Lumbar extension</p>
<p class="tbodyc">Preserved pulses</p></td>
<td class="th1"><p class="tbodyc">Diminished/absent pulses</p>
<p class="tbodyc">(dorsalis pedis/posterior tibialis) Pallor</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Diagnostic studies</p></td>
<td class="th1"><p class="tbodyc">MRI lumbar spine</p>
<p class="tbodyc">CT myelogram (if no MRI)</p>
<p class="tbodyc">EMG/NCS</p></td>
<td class="th1"><p class="tbodyc">Arterial Doppler studies</p>
<p class="tbodyc">Ankle-brachial index (ABI) Arteriography</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Treatment</p></td>
<td class="th1"><p class="tbodyc">PT (flexion exercise), NSAIDs,</p>
<p class="tbodyc">epidural steroid injections (ESI)</p>
<p class="tbodyc">Surgery (if other Rx fails)</p></td>
<td class="th1"><p class="tbodyc">Modify vascular risk factors, exercise rehab, antiplatelet Rx, revascularization</p></td>
</tr>
</tbody>
</table>
<p class="tfn">Nb, diagnosis complicated by overlap between presentations &amp; possibility of both diagnoses in the same patient.</p>
<p class="h">Evaluation &amp; treatment of nerve root compression <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2016;374:1763)</span></p>
<p class="noindent1">• MRI if sx not improved after 6 wk of conservative tx; if nondiagnostic, consider EMG/NCS</p>
<p class="noindent1">• Conservative: avoid bending/lifting; soft collar (cervical radiculopathy); NSAIDs; muscle relaxants; lidocaine patch/ointment; Rx neuropathic pain (see “Peripheral Neuropathies”); physical/occup therapy. Insufficient evidence for oral steroids.</p>
<p class="noindent1">• Avoid opiates when possible; risks outweigh benefits in noncancerous back pain</p>
<p class="noindent1">• Spinal epidural steroid injections (ESI): limited short-term relief of refractory radicular pain</p>
<p class="noindent1">• Surgery: cord compression or cauda equina syndrome; progressive motor dysfunction/EMG/NCS pathologic findings; bowel/bladder dysfunction; intractable pain w/ failure to respond to conservative Rx after 3 mo</p>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../j09u21sl.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-96ac16803db7461d85d0589a1c192bcf">Cover</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-96ac16803db7461d85d0589a1c192bcf">Title Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-96ac16803db7461d85d0589a1c192bcf">Copyright Page</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-96ac16803db7461d85d0589a1c192bcf">Contents</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-96ac16803db7461d85d0589a1c192bcf">Contributing Authors</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-96ac16803db7461d85d0589a1c192bcf">Foreword</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-96ac16803db7461d85d0589a1c192bcf">Preface</a>
    </li>
    <li>
      <a href="part0007.html#6LJU0-96ac16803db7461d85d0589a1c192bcf">CARDIOLOGY</a>
      <ul>
        <li>
          <a href="part0007.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0007.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0007.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0007.html#h4">Coronary Angiography &amp; PCI</a>
        </li>
        <li>
          <a href="part0007.html#h5">Stable Ischemic Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h6">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h7">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0007.html#h8">Heart Failure</a>
        </li>
        <li>
          <a href="part0007.html#h9">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0007.html#h10">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h11">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0007.html#h12">Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h13">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0007.html#h14">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h15">Arrhythmias</a>
        </li>
        <li>
          <a href="part0007.html#h16">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0007.html#h17">Syncope</a>
        </li>
        <li>
          <a href="part0007.html#h18">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0007.html#h19">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0007.html#h20">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-96ac16803db7461d85d0589a1c192bcf">PULMONARY</a>
      <ul>
        <li>
          <a href="part0008.html#h21">Dyspnea</a>
        </li>
        <li>
          <a href="part0008.html#h22">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0008.html#h23">Asthma</a>
        </li>
        <li>
          <a href="part0008.html#h24">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0008.html#h25">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0008.html#h26">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0008.html#h27">Hemoptysis</a>
        </li>
        <li>
          <a href="part0008.html#h28">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0008.html#h29">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0008.html#h30">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0008.html#h31">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0008.html#h32">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0008.html#h33">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0008.html#h34">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0008.html#h35">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0008.html#h36">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0008.html#h37">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0008.html#h38">Toxicology</a>
        </li>
        <li>
          <a href="part0008.html#h39">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-96ac16803db7461d85d0589a1c192bcf">GASTROENTEROLOGY</a>
      <ul>
        <li>
          <a href="part0009.html#h40">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0009.html#h41">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0009.html#h42">Diarrhea</a>
        </li>
        <li>
          <a href="part0009.html#h43">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0009.html#h44">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0009.html#h45">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0009.html#h46">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0009.html#h47">Pancreatitis</a>
        </li>
        <li>
          <a href="part0009.html#h48">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0009.html#h49">Hepatitis</a>
        </li>
        <li>
          <a href="part0009.html#h50">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0009.html#h51">Cirrhosis</a>
        </li>
        <li>
          <a href="part0009.html#h52">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h53">Ascites</a>
        </li>
        <li>
          <a href="part0009.html#h54">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-96ac16803db7461d85d0589a1c192bcf">NEPHROLOGY</a>
      <ul>
        <li>
          <a href="part0010.html#h55">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0010.html#h56">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h57">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h58">Kidney Disease</a>
        </li>
        <li>
          <a href="part0010.html#h59">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0010.html#h60">Urinalysis</a>
        </li>
        <li>
          <a href="part0010.html#h61">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-96ac16803db7461d85d0589a1c192bcf">HEMATOLOGY-ONCOLOGY</a>
      <ul>
        <li>
          <a href="part0011.html#h62">Anemia</a>
        </li>
        <li>
          <a href="part0011.html#h63">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0011.html#h64">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0011.html#h65">Coagulopathies</a>
        </li>
        <li>
          <a href="part0011.html#h66">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0011.html#h67">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0011.html#h68">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h69">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0011.html#h70">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0011.html#h71">Leukemia</a>
        </li>
        <li>
          <a href="part0011.html#h72">Lymphoma and CLL</a>
        </li>
        <li>
          <a href="part0011.html#h73">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0011.html#h74">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0011.html#h75">Lung Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h76">Breast Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h77">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h78">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h79">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h80">Other Solid Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h81">Immunotherapy &amp; Cellular Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h82">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0011.html#h83">Chemo Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-96ac16803db7461d85d0589a1c192bcf">INFECTIOUS DISEASES</a>
      <ul>
        <li>
          <a href="part0012.html#h84">Pneumonia</a>
        </li>
        <li>
          <a href="part0012.html#h85">Fungal Infections</a>
        </li>
        <li>
          <a href="part0012.html#h86">Infxns in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0012.html#h87">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0012.html#h88">Sexually Transmitted Infections</a>
        </li>
        <li>
          <a href="part0012.html#h89">Skin and Soft Tissue Infections</a>
        </li>
        <li>
          <a href="part0012.html#h90">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0012.html#h91">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0012.html#h92">Tuberculosis</a>
        </li>
        <li>
          <a href="part0012.html#h93">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0012.html#h94">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0012.html#h95">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-96ac16803db7461d85d0589a1c192bcf">ENDOCRINOLOGY</a>
      <ul>
        <li>
          <a href="part0013.html#h96">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h97">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h98">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h99">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h100">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0013.html#h101">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-96ac16803db7461d85d0589a1c192bcf">RHEUMATOLOGY</a>
      <ul>
        <li>
          <a href="part0014.html#h102">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0014.html#h103">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0014.html#h104">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0014.html#h105">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0014.html#h106">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0014.html#h107">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0014.html#h108">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0014.html#h109">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0014.html#h110">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0014.html#h111">Vasculitis</a>
        </li>
        <li>
          <a href="part0014.html#h112">Autoinflammatory Syndromes</a>
        </li>
        <li>
          <a href="part0014.html#h113">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-96ac16803db7461d85d0589a1c192bcf">NEUROLOGY</a>
      <ul>
        <li>
          <a href="part0015.html#h114">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0015.html#h115">Seizures</a>
        </li>
        <li>
          <a href="part0015.html#h116">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0015.html#h117">Dizziness</a>
        </li>
        <li>
          <a href="part0015.html#h118">Stroke</a>
        </li>
        <li>
          <a href="part0015.html#h119">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0015.html#h120">Headache</a>
        </li>
        <li>
          <a href="part0015.html#h121">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-96ac16803db7461d85d0589a1c192bcf">CONSULTS</a>
      <ul>
        <li>
          <a href="part0016.html#h122">Surgical Issues</a>
        </li>
        <li>
          <a href="part0016.html#h123">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0016.html#h124">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-96ac16803db7461d85d0589a1c192bcf">APPENDIX</a>
      <ul>
        <li>
          <a href="part0017.html#h125">ICU Medications</a>
        </li>
        <li>
          <a href="part0017.html#h126">Antibiotics</a>
        </li>
        <li>
          <a href="part0017.html#h127">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0018.html#H5A40-96ac16803db7461d85d0589a1c192bcf">ABBREVIATIONS</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-96ac16803db7461d85d0589a1c192bcf">INDEX</a>
    </li>
    <li>
      <a href="part0020.html#J2B80-96ac16803db7461d85d0589a1c192bcf">PHOTO INSERTS</a>
      <ul>
        <li>
          <a href="part0020.html#h128">Radiology</a>
        </li>
        <li>
          <a href="part0020.html#h129">Echocardiography</a>
        </li>
        <li>
          <a href="part0020.html#h130">Coronary Angiography</a>
        </li>
        <li>
          <a href="part0020.html#h131">Peripheral Blood Smears</a>
        </li>
        <li>
          <a href="part0020.html#h132">Leukemias</a>
        </li>
        <li>
          <a href="part0020.html#h133">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0021.html#K0RQ0-96ac16803db7461d85d0589a1c192bcf">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0014.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../j09u21sl.html" class="calibreAHome">start
</a>

    
      <a href="part0016.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
